Moreover, regarding the limitations of anti-CCL2 monotherapies in chronic inflammatory disorders such as RA and OA, it is possible that combining anti-TNF-α and anti-CCL2 antibodies can be a potential approach in treating OA. Here, CCL2 is linked to rheumatoid arthritis.